All Categories
Ulli Seibel, CEO of AlzChem Group AG, informed the Supervisory Board today that he will leave the company on December 31, 2019 for personal reasons.
Sales in 2018 increase by 6.0% to 375.2 million euros EBITDA in 2018 rises by 8.1% to EUR 49.4 million Dividend proposal of EUR 0.09 for short fiscal year from July to December 2018 Forecast 2019: sales growth to EUR 389.9 to 398.9 million with stable EBITDA
With its creatine product LIVADUR®, AlzChem Group AG will be addressing end consumers directly for the first time as of March 2019. The target audience consists of active people aged 55 and over who want to prevent the age-related decline in muscle strength and thus maintain their high quality of life and fitness. The dietary supplement is based on the already very successful product Creapure®, the only creatine product manufactured in Germany that is supplied to the dietary supplement industry specifically for sports nutrition.
Acetylene (C2H2) is the world's most efficient and hottest burning standard welding gas. For producing acetylene, the reaction of calcium carbide (CaC2) with water (H2O) is used, whereas acetylene and lime milk (Ca(OH)2) is generated.
The shareholders of AlzChem Group AG, a vertically integrated specialty chemicals supplier with leading market positions in selected niche markets, approved all agenda items with a large majority at today's Annual General Meeting. In addition to the discharge of the Management Board and Supervisory Board, it was also decided to pay a dividend of EUR 0.11 per share to the shareholders.
Sales increase from EUR 89.9 million to EUR 92.0 million EBITDA rises from EUR 10.3 million to EUR 10.4 million Forecast confirmed
AlzChem Group AG's (ISIN: DE000A0AHT46, ticker: SFP1) three majority shareholders, namely LIVIA Corporate Development SE, HDI Vier CE GmbH, and four two na GmbH, successfully sold in total 20,454,546 existing bearer shares with no par value in AlzChem Group AG, corresponding to approximately 20.1% of all outstanding bearer shares, in a private placement to institutional investors.
Today, AlzChem Group AG‘s three majority shareholders, namely LIVIA Corporate Development SE, HDI Vier CE GmbH, and four two na GmbH, published their decision to place existing shares in AlzChem Group AG, increasing the free-float in AlzChem’s ordinary bearer shares from approximately 1.2% to between approximately 21.3% and 28.0%, depending on the full placement size.